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Abstract
Background: There is increasing evidence of high platinum sensitivity in BRCA-associated breast cancer. However,
evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based
chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting.
Methods: A retrospective study was performed by obtaining information from patient files. The results were
compared with the available data from a literature review.
Results: Twelve female patients with BRCA1 gene mutations who had stage I to III breast cancers were eligible for
evaluation. They received platinum-based neoadjuvant chemotherapy between 2011 and 2016. Eleven patients
received a combination of cisplatin and doxorubicin, and one patient received carboplatin and docetaxel. All
patients underwent mastectomy after chemotherapy. Ten patients (83%) achieved pathological complete remission
(pCR). The observed pCR rate was comparable to existing results found in similar studies.
Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based
neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role
of platinum-based therapies in BRCA1-positive breast cancer.
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Background
Hereditary breast cancer accounts for approximately
5–10% of all breast cancer cases. BRCA1/2 gene mutations
are responsible for approximately two-thirds of hereditary
breast cancers [1]. The BRCA genes are tumor suppressor
genes that encode proteins that are involved in homolo-
gous recombination (HR) repair. HR is the most common
repair mechanism for double strand breaks during the
DNA replication process. Mutations in the BRCA gene re-
sult in genomic instability and subsequent malignant
processes. The platinum agent introduces intra-strand
crosslinks. Due to faulty DNA-repair proteins from the
pathogenic BRCA1 mutation, cellular protein synthesis and
replication are reduced, and eventually, cells undergo
apoptosis. BRCA-associated breast cancers are often triple
negative breast cancers (TNBCs). Due to significant differ-
ences in chemotherapy sensitivity that depend on hormone
receptor status, various chemotherapy regimens have been
tested in adjuvant and neoadjuvant settings for BRCA-
associated breast cancer. Attempts to understand the role
of BRCA genes in and sensitivity of cancer cells to DNA
damaging agents in BRCA mutation carriers have reestab-
lished interest in platinum agents in the context of breast
cancer treatment.
Several studies have shown the sensitivity of BRCA-
related breast cancer to platinum agents, such as cisplatin
and carboplatin, and more studies will follow. The ESMO
clinical practice guidelines [2] for primary breast cancer
published in 2015 do not recommend platinum agents for
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routine use for BRCA1/2 mutation carriers; however,
these guidelines state that adding a platinum compound
to NACT, after discussion with the patient, is acceptable.
The ESO-ESMO 3rd international consensus guidelines
for advanced breast cancer (ABC3) [3] published on De-
cember 5th, 2016, recommend a platinum regimen
chemotherapy for BRCA-associated TNBC if not previ-
ously administered.
The aim of this study was to retrospectively evaluate
platinum-based neoadjuvant chemotherapy for BRCA1-
positive breast cancers.
Methods
A retrospective evaluation was made of platinum-based
neoadjuvant chemotherapy in breast cancer patients with
BRCA1 gene mutations who were treated at the breast unit
at Pauls Stradins Clinical University Hospital (PSCUH). Pa-
tient data were collected from the hospital database, along
with the respective patient history and chemotherapy chart
from the Clinic of Oncology at PSCUH. This retrospective
evaluation was approved by Riga Stradins University
Ethical committee (Nr.55/ 27.10.2016). Patients with diag-
nosed invasive breast cancers and confirmed BRCA1 gene
mutations who received platinum-based chemotherapy in
the neoadjuvant setting were included in the evaluation.
Genomic DNA was isolated from peripheral blood cells
using the FlexiGene DNA Kit (Qiagen, Germany). Screen-
ing of the three most common BRCA1 mutations in
Latvia, namely, c.4035delA (BIC: 4154delA), c.5266dupC
(BIC: 5382insC) and c.181 T >G (BIC: 300 T >G/C61G),
was performed by multiplex PCR.
Insufficient patient data was the exclusion criterion.
Pathological complete response was defined as the
complete disappearance of an invasive tumor. The
follow-up time was the time from mastectomy to Febru-
ary 2017.
Study population
Twelve BRCA-associated patients were eligible for this
evaluation during the period from 2011 to February 2017.
The clinical characteristics of the patients are pre-
sented in Table 1. All patients except one received a
regimen of 50–75 mg/m2 cisplatin and 50–60 mg/m2
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doxorubicin (one patient received carboplatin AUC5 and
75 mg/m2 docetaxel) every 3weeks for three to 6 cycles.
The treatment regimens are presented in Table 2. Four
patients had received postoperative radiation therapy.
One patient had received additional adjuvant cisplatin
and doxorubicin for 2 cycles. Seven patients (58%)
received 6 cycles with platinum agents in all cycles.
All 12 patients (100%) underwent therapeutic mastec-
tomies on the affected side and risk reductive mastecto-
mies on the contralateral side if applicable, except one
patient who refused risk reductive mastectomy. A total
of 23 mastectomies were performed in 12 patients: three
simple, six skin-sparing and 14 nipple-sparing mastecto-
mies. In 10 out of 12 cases immediate reconstruction
was carried out. Five patients (42%) had prophylactic
salpingoophorectomies performed after breast surgery.
The mean observation time after breast surgery was 24
(range one - 63 months). Toxicity was not assessed in
this evaluation.
Results
Ten (83%) out of 12 patients achieved pCR after neoad-
juvant chemotherapy. Two patients (17%) had residual
cancer after NACT with partial response or stable dis-
ease. The proportions of the subgroups of those who
achieved pCR are presented in Table 3. The pCR rates
according to clinical stage I, II and III were 100%, 86%
and 50%, respectively. Eight (80%) out of 10 patients
with confirmed negative estrogen and progesterone re-
ceptor status achieved pCR. Five (83%) out of six pa-
tients with positive lymph node status prior to surgery
achieved pCR. (Similarly, five (83%) out of six patients
with node-negative disease achieved pCR).
Eleven patients are alive today, and one patient died
due to brain metastases 15 months after breast cancer
diagnosis. All 10 patients with pCR are disease free to
date according to the available data. The mean observa-
tion time for the patient group with pCR is 25 months
(range 6 – 63 months). Table 4 presents the characteris-
tics of the two patients who did not achieve pCR.
Discussion
Our findings from the retrospective evaluation at the
breast unit of PSCUH suggested that platinum-based neo-
adjuvant chemotherapy was highly effective in breast can-
cer patients with BRCA1 gene mutations. In our patient
group, 12 patients received platinum-based NACT. pCR
was observed in10 patients (83%), and partial remission or
stable disease was observed in two patients (17%). T. Byrski
et al. [4] were the first to apply platinum-based chemother-
apy in studies targeting BRCA mutation carriers specific-
ally. As seen in Table 5, the pCR rates ranged from 59% to
83% in the evaluated studies. Our results matched these
findings and confirmed the sensitivity of BRCA-associated
breast cancer to platinum agents. In the neoadjuvant
studies by T. Byrski [4, 5] and V. Moysienko [6], the au-
thors applied cisplatin monotherapy. The patients in the
current evaluation received cisplatin and doxorubicin (one
patient received carboplatin and docetaxel). There were no
available data on this combination for patients with BRCA-
associated breast cancer. The results indicated that the
addition of anthracycline to a platinum agent in the neoad-
juvant setting produces equivalent or better results than
monotherapy in terms of pCR. Most of the12 patients in-
cluded in this evaluation had cancers that were diagnosed
early. Seven patients had stage II, three patients had stage
I, and two patients had stage III. These characteristics are
comparable to the trial of T. Byrski et al. [5], where a pCR
of 61% was achieved.
Table 3 Proportions of patient subgroups achieving pCR
Characteristic No. with pCR Total no. % PCR
Age, years
20–40 8 8 100
41–50 1 2 50
51–60 1 2 50
Stage
I 3 3 100
II 6 7 86
III 1 2 50
Estrogen receptor
Positive 1 1 100
Negative 8 10 80
Missing 1 1 100
Lymph nodes
Positive 5 6 83
Negative 5 6 83
Table 2 NACT regimens of patients evaluated
Agents Dosages Cycles No. of
patients
Fluorouracil + doxorubicin +
cyclophosphamide (FAC)
Cisplatin + doxorubicin
500 mg/m2 + 50 mg/m2 +
500 mg/m2











Cisplatin + doxorubicin 50 mg/m2 + 50 mg/m2 6 3
75 mg/m2 + 50 mg/m2 5 1
60 mg/m2 + 60 mg/m2 6 2
60 mg/m2 + 60 mg/m2 4 1
75 mg/m2 + 50 mg/m2 4 1
50 mg/m2 + 60 mg/m2 6 1
Carboplatin + docetaxel AUC-5 + 60 mg/m2 6 1
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The BRCA1 founder mutations in our study included
c.4035delA (BIC: 4154delA) and c.5266dupC (BIC:
5382insC). These are the same mutations examined in
the study by Byrski et al.; however, C61G was also
included in their study population but not in ours.
Our results need to be verified in populations with
other mutations.
The protocols for all patients in the reviewed neoadju-
vant studies included the administration of the standard
AC regimen as the adjuvant chemotherapy regardless of
the level of response. The patients who achieved pCR in
our study did not receive any adjuvant chemotherapy.
Our observation times for patients with pCR varied from
1month to 63 months, and currently, the mean observa-
tion time is 25 months. All patients except one are still
alive according to the available data. A comprehensive
assessment of the survival rate of our platinum-based
NACT will require additional follow-up. Observing the
progression-free survival (PFS) rate of our patient group
with pCR will provide highly interesting information in
the future. No studies have properly assessed PFS that is
specific to breast cancer patients with BRCA1 mutations
receiving only neoadjuvant platinum-based chemother-
apy without adjuvant treatment.
Platinum agents also showed efficacy for BRCA1
mutation carriers with advanced breast cancer. A
BRCA1 gene mutation was a good predictor of an
increased response rate compared with wild-type
BRCA1 [7–9]. The best evidence on platinum efficacy
compared to standard therapy to date is presented by
Telli et al. in the TNT trial [7]. The authors randomized
carboplatin vs docetaxel in patients with metastatic
TNBC. They observed a carboplatin response rate of
68% vs a docetaxel rate of 33% (P = 0.03) in the sub-
group of 43 patients having BRCA1/2 mutations. Further
research is needed on metastatic BRCA-associated
breast cancer.
There is a substantial amount of research on TNBC. In
a study comprising 1824 patients with TNBC unselected
for family history, 8.5% had a BRCA1 mutation, and 2.7%
had a BRCA2 mutation [10]. The patients with BRCA-
associated breast cancer represent a small subset of breast
cancer patients. This is probably the reason for the lack of
data for this specific patient population. To date, there are
no available data from randomized trials that specifically
target BRCA1 gene mutation carriers with breast cancer.
Evidence from the Maksimenko study [11] indicated that
carriers of a germline BRCA1 founder mutation (4153delA
a 5382insC) had significantly improved prognoses at any
stage compared to carriers of wild-type BRCA who had
TNBC, even though only 7.8% of patients in this study
had received platinum-based chemotherapy. These re-
sults may indicate that BRCA1 mutation carriers have
higher chemosensitivity.
Table 5 Platinum-based neoadjuvant chemotherapy in BRCA-associated breast cancer
Author n Setting Regimen Efficacy
Byrski et al. 2010 [4] 12 Neoadjuvant Cisplatin pCR rate: 83%
Byrski et al. 2014 [5] 107 Neoadjuvant Cisplatin pCR rate: 61%
Moiseyenko et al. 2015 [6] 5 Neoadjuvant Cisplatin pCR rate: 60%
Sharma et al. 2016 [13] 30 Neoadjuvant Carboplatin+Docetaxel pCR rate: 59%




Histology Ductal carcinoma Ductal carcinoma
Grade 3 3
ER/PR/HER2 Triple negative Triple negative
NACT regimen FAC (1000 mg + 100 mg + 1000 mg) 3 cyclesCisplatin+
Doxorubicin (140 mg + 110 mg) 3 cycles
Cisplatin+Doxorubicin (80 mg + 90 mg 4 cycles,
80 mg + 85 mg 2 cycles)
Pre-tx tumor size 45 mm X (extensive, diffuse, difficult to evaluate the size)
Post-tx tumor size 25 mm 65 mm
Operation Unilateral mastectomy Bilateral mastectomy
Lymphadenectomy Yes Yes
Adjuvant CT No No
Postoperative radiation Yes Yes
Progression No Brain metastases, PFS 12 months, OS 15 months
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The toxicity of chemotherapy was not evaluated. Plat-
inum agents are known to cause mild to severe toxicity
[12]. Cisplatin seems to be the drug that has the most
evidence of efficacy in BRCA-associated breast cancer.
No evidence from randomized trials exists on which
platinum agent is more effective in BRCA-associated
breast cancer. Further data are needed. A transition from
cisplatin to carboplatin-based chemotherapy would likely
benefit patients in terms of fewer side effects and higher
tolerance to recommended platinum dosages.
Conclusion
The results of the study confirm the high pCR rate of
BRCA1-positive breast cancer after platinum-based neoad-
juvant chemotherapy. Larger randomized studies and lon-
ger follow-up times are necessary to evaluate the role of
platinum-based therapies in BRCA1-positive breast cancer.
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